Low-Density Lipoprotein Cholesterol Control as a Performance Measure: A National Analysis of the VHA.

Competing Interests: Funding Support and Author Disclosures Dr Sandhu is supported by National Heart, Lung, and Blood Institute grant 1K23HL151672. Dr Rodriguez was funded by NIH National Heart, Lung, and Blood Institute grants 1K01HL144607, R01HL168188, and R01HL167974, the American Heart Association/Harold Amos Medical Faculty Development program, and Doris Duke Foundation Grant #2022051. Dr Jain has received consulting fees from Bristol Myers Squibb, ARTIS Ventures, and Broadview Ventures outside of the submitted work. Dr Bhatt has received research grant support to his institution from National Institutes of Health/National Heart, Lung, and Blood Institute, National Institutes of Health/National Institute on Aging, American College of Cardiology Foundation, and the Centers for Disease Control and Prevention; and has received consulting fees from Sanofi Pasteur, Merck, and Novo Nordisk. Dr Sandhu has received consulting fees from Lexicon Pharmaceuticals; and has received research funding from the American Heart Association, Novartis Pharmaceuticals, and Reprieve Cardiovascular outside of the submitted work. Dr Rodriguez has received equity from Carta Healthcare and HealthPals; and has received consulting fees from HealthPals, Novartis, NovoNordisk, Esperion Therapeutics, Movano Health, Kento Health, Inclusive Health, Edwards, Arrowhead Pharmaceuticals, HeartFlow, and iRhythm outside the submitted work. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.